Jan 28, 2026 | Press Releases
January 26 Presentation highlighted Entolimod’s potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposureBARDA has requested a follow-up meeting to continue the discussion on the potential utility of...
Jan 20, 2026 | Press Releases
Presentation will Cover Recent Corporate Milestones Including Acceleration of Manufacturing Readiness for Entolimod™ FREMONT, CA / ACCESS Newswire / January 20, 2026 / Tivic Health® Systems, Inc. (NASDAQ:TIVC), a late-stage immunotherapeutics company, today...
Jan 12, 2026 | Press Releases
Company demonstrates commercial-scale production of its Toll-like Receptor 5 (TLR5) agonist for Acute Radiation Syndrome (ARS) and Neutropenia through wholly owned contract development manufacturing organization (CDMO), Velocity BioworksCompany’s next step is to...
Jan 8, 2026 | Press Releases
Conference Call to be Hosted on Monday, January 12 at 1:30 PM PT/4:30 PM ET FREMONT, CA / ACCESS Newswire / January 8, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage immunotherapeutics company, today announced that Management will host a special...
Dec 11, 2025 | Press Releases
Acquisition creates additional near-term revenue opportunities from newly formed Contract Development and Manufacturing Organization (CDMO) subsidiary, Velocity Bioworks™ Financing led by 3i, LP includes $16M debt financing for the purchase of assets and up to $75M in...